Thermo Fisher Scientific and Roche Renew Partnership for Improved Detection of Sepsis Using PCT Biomarker

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HENNIGSDORF, Germany--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the renewal of its non-exclusive, long-term, royalty-bearing agreement with Roche for the use of Thermo Fisher’s Procalcitonin (B.R.A.H.M.S PCTTM) technology, currently available as an automated immunoassay on the Roche Elecsys® cobas e platforms in all countries outside the United States. The agreement extends a long-standing relationship between the companies.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC